Log in

NASDAQ:BNGOBioNano Genomics Stock Price, Forecast & News

-0.08 (-14.13 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $0.49
50-Day Range
MA: $0.47
52-Week Range
Now: $0.49
Volume22.40 million shs
Average Volume14.77 million shs
Market Capitalization$40.79 million
P/E RatioN/A
Dividend YieldN/A
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:BNGO



Sales & Book Value

Annual Sales$10.13 million
Book Value$0.11 per share


Net Income$-29,820,000.00
Net Margins-344.98%
Return on Equity-15,212.64%


Market Cap$40.79 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive BNGO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.

BioNano Genomics (NASDAQ:BNGO) Frequently Asked Questions

How has BioNano Genomics' stock been impacted by COVID-19 (Coronavirus)?

BioNano Genomics' stock was trading at $0.5770 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BNGO stock has decreased by 15.8% and is now trading at $0.4861. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioNano Genomics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNano Genomics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioNano Genomics.

When is BioNano Genomics' next earnings date?

BioNano Genomics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioNano Genomics.

How were BioNano Genomics' earnings last quarter?

BioNano Genomics Inc (NASDAQ:BNGO) announced its earnings results on Thursday, June, 18th. The company reported ($0.30) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.08. The firm earned $1.14 million during the quarter, compared to analyst estimates of $1.10 million. BioNano Genomics had a negative return on equity of 15,212.64% and a negative net margin of 344.98%. View BioNano Genomics' earnings history.

What guidance has BioNano Genomics issued on next quarter's earnings?

BioNano Genomics updated its first quarter 2020 After-Hours earnings guidance on Thursday, May, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.1-1.1 million, compared to the consensus revenue estimate of $1.9 million.

What price target have analysts set for BNGO?

3 brokerages have issued 1 year target prices for BioNano Genomics' stock. Their forecasts range from $1.00 to $3.00. On average, they anticipate BioNano Genomics' stock price to reach $1.83 in the next twelve months. This suggests a possible upside of 277.2% from the stock's current price. View analysts' price targets for BioNano Genomics.

What are Wall Street analysts saying about BioNano Genomics stock?

Here are some recent quotes from research analysts about BioNano Genomics stock:
  • 1. According to Zacks Investment Research, "BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. " (6/29/2020)
  • 2. Maxim Group analysts commented, "Bionano reported 2Q19 with revenues of $2.2M and a net loss of ($7.7M). The company ended the period with $15.3M in cash on the balance sheet." (8/9/2019)

Has BioNano Genomics been receiving favorable news coverage?

Media coverage about BNGO stock has been trending negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioNano Genomics earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news about BioNano Genomics.

Who are some of BioNano Genomics' key competitors?

What other stocks do shareholders of BioNano Genomics own?

Who are BioNano Genomics' key executives?

BioNano Genomics' management team includes the following people:
  • Dr. Robert Erik Holmlin, Pres, CEO & Director (Age 51)
  • Mr. Michael J. Ward, Chief Financial Officer (Age 47)
  • Mr. Warren Robinson, Chief Commercial Officer (Age 50)
  • Mr. Mark Borodkin, Chief Operating Officer (Age 45)
  • Heather Adams, Sec.

When did BioNano Genomics IPO?

(BNGO) raised $16 million in an initial public offering on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is BioNano Genomics' stock symbol?

BioNano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

How do I buy shares of BioNano Genomics?

Shares of BNGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioNano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $0.49.

How big of a company is BioNano Genomics?

BioNano Genomics has a market capitalization of $40.79 million and generates $10.13 million in revenue each year. The company earns $-29,820,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. BioNano Genomics employs 77 workers across the globe.

What is BioNano Genomics' official website?

The official website for BioNano Genomics is www.bionanogenomics.com.

How can I contact BioNano Genomics?

BioNano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company can be reached via phone at 858-888-7600 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.